Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
- PMID: 18418596
- DOI: 10.1007/s00259-008-0769-2
Comparison between 68Ga-DOTA-NOC and 18F-DOPA PET for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours
Abstract
Purpose: (18)F-FDG positron emission tomography (PET) value for the assessment of neuro-endocrine tumours (NET) is limited. Preliminary studies indicate that (18)F-DOPA and (68)Ga-DOTA-NOC are more accurate for disease assessment and (68)Ga-DOTA peptides provide additional data on receptor status that are crucial for targeted radionuclide therapy. At present, there are no comparative studies investigating their role in NET.
Aim: The aim of this study was to compare (68)Ga-DOTA-NOC and (18)F-DOPA for the evaluation of gastro-entero-pancreatic and lung neuro-endocrine tumours.
Materials and methods: Thirteen patients with biopsy-proven NET (gastro-entero-pancreatic or pulmonary) were prospectively enrolled and scheduled for (18)F-DOPA and (68)Ga-DOTA-NOC PET. PET results obtained with both tracers were compared with each other, with other conventional diagnostic procedures (CT, ultrasound) and with follow-up (clinical, imaging).
Results: The most common primary tumour site was the pancreas (8/13) followed by the ileum (2/13), the lung (2/13) and the duodenum (1/13). The carcinoma was well differentiated in 10/13 and poorly differentiated in 3/13 cases. (68)Ga-DOTA-NOC PET was positive, showing at least one lesion, in 13/13 cases while (18)F-DOPA PET was positive in 9/13. On a lesions basis, (68)Ga-DOTA-NOC identified more lesions than (18)F-DOPA (71 vs 45), especially at liver, lung and lymph node level. (68)Ga-DOTA-NOC correctly identified the primary site in six of eight non-operated cases (in five cases, the primary was surgically removed before PET), while (18)F-DOPA identified the primary only in two of eight cases.
Conclusions: Although the patients studied are few and heterogeneous, our data show that (68)Ga-DOTA-NOC is accurate for the detection of gastro-entero-pancreatic and lung neuro-endocrine tumours in either the primary or metastatic site and that it offers several advantages over (18)F-DOPA.
Similar articles
-
Evaluation of unusual neuroendocrine tumours by means of 68Ga-DOTA-NOC PET.Biomed Pharmacother. 2008 Dec;62(10):667-71. doi: 10.1016/j.biopha.2008.01.010. Epub 2008 Mar 3. Biomed Pharmacother. 2008. PMID: 18358680
-
Head-to-head comparison between [68Ga]Ga-DOTA-NOC and [18F]DOPA PET/CT in a diverse cohort of patients with pheochromocytomas and paragangliomas.Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1989-2001. doi: 10.1007/s00259-024-06622-z. Epub 2024 Feb 1. Eur J Nucl Med Mol Imaging. 2024. PMID: 38300262
-
Dual tracer functional imaging of gastroenteropancreatic neuroendocrine tumors using 68Ga-DOTA-NOC PET-CT and 18F-FDG PET-CT: competitive or complimentary?Clin Nucl Med. 2014 Jan;39(1):e27-34. doi: 10.1097/RLU.0b013e31827a216b. Clin Nucl Med. 2014. PMID: 24217539
-
Head-to-head comparison between 18 F-DOPA PET/CT and 68 Ga-DOTA peptides PET/CT in detecting intestinal neuroendocrine tumours: A systematic review and meta-analysis.Clin Endocrinol (Oxf). 2021 Oct;95(4):595-605. doi: 10.1111/cen.14527. Epub 2021 Jun 19. Clin Endocrinol (Oxf). 2021. PMID: 34018606
-
Current status and future prospects of PET-imaging applications in patients with gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs).Eur J Radiol. 2021 Oct;143:109932. doi: 10.1016/j.ejrad.2021.109932. Epub 2021 Aug 25. Eur J Radiol. 2021. PMID: 34482177 Review.
Cited by
-
Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.J Clin Med. 2022 Nov 18;11(22):6836. doi: 10.3390/jcm11226836. J Clin Med. 2022. PMID: 36431313 Free PMC article. Review.
-
18F-fluorodihydroxyphenylalanine vs other radiopharmaceuticals for imaging neuroendocrine tumours according to their type.Eur J Nucl Med Mol Imaging. 2013 Jun;40(6):943-66. doi: 10.1007/s00259-013-2342-x. Epub 2013 Feb 16. Eur J Nucl Med Mol Imaging. 2013. PMID: 23417499 Free PMC article. Review.
-
⁶⁸Ga-labelled peptides for diagnosis of gastroenteropancreatic NET.Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1:S52-60. doi: 10.1007/s00259-011-1989-4. Eur J Nucl Med Mol Imaging. 2012. PMID: 22388622 Review.
-
Nuclear medicine imaging of neuroendocrine tumours.Clin Med (Lond). 2012 Aug;12(4):377-80. doi: 10.7861/clinmedicine.12-4-377. Clin Med (Lond). 2012. PMID: 22930887 Free PMC article. No abstract available.
-
Endocrine tumors: the evolving role of positron emission tomography in diagnosis and management.J Endocrinol Invest. 2010 Jan;33(1):54-60. doi: 10.1007/BF03346550. Epub 2009 Oct 9. J Endocrinol Invest. 2010. PMID: 19820296 Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical